cyrilzakka/clinical-trials huggingface dataset:
Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones

The aims of this study are to collect prospective data on the natural history of bone metastases (BMs) and skeleta related events (SREs),

The aims of this study are to evaluate clinical and biological factors of patients with BMs after reconstruction with intramedullary fixation (IMN) or endoprosthetic reconstruction (EPR) with a specific focus on (1) the rate of complication or failure; (2) differences in complication rates by anatomic site; (3) functional results as assessed by the Musculoskeletal Tumor Society System (MSTS); (4) differences in complication rate between patients treated with INM versus EPR; and (5) differences in survival in patients with metastatic bone disease based on disease-specific, laboratory, and demographic information.

Eligibility Criteria:
Inclusion Criteria:

* Patients with long bone metastases treated surgically with intramedullary nail or endoprosthetic reconstruction

Exclusion Criteria:

* Patients with bone metastases of the spine
Virtual Reality Application in Chemotherapy

The present study wants to design a training program for chemotherapy with using VR. Then the investigators design a protocol to compare the training effects in the VR program and ISO document.

As technology advances, mobile devices have gradually turned into wearable devices. Furthermore, virtual reality (VR), augmented reality (AR), and mixed reality (MR) are being increasingly applied in medical fields such as medical education and training, surgical simulation, neurological rehabilitation, psychotherapy, and telemedicine. Research results demonstrate the ability of VR, AR, and MR to ameliorate the inconveniences that are often associated with traditional medical care, reduce incidents of medical malpractice caused by unskilled operations, and reduce the cost of medical education and training. What is more, the application of these technologies has enhanced the effectiveness of medical education and training, raised the level of diagnosis and treatment, improved the doctor-patient relationship, and boosted the efficiency of medical execution. The present study wants to design a training program for chemotherapy with using VR. Then the investigators design a protocol to compare the training effects in VR program and ISO document.

Eligibility Criteria:
Inclusion Criteria:

1. The staffs who require to implement chemotherapy skill in the hospital.
2. Age over 20 years.

Exclusion Criteria:

1. Refuse to join the study.
IntellO2 vs Manual Control for Optimizing Oxygenation in Infants

The overall objective of this study is to demonstrate that the IntellO2 device providing automated control of fraction of inspired oxygen (FiO2) adjustments in spontaneously breathing infants with fluctuating arterial blood oxygen saturation levels is safe and efficacious in the routine clinical environment. Specifically, it is hypothesized that the IntellO2 will perform as well or better than standard practice for maintaining infants' arterial blood oxygen saturation in a target range while minimizing the exposure to elevated levels of oxygen in the inspired gas.


Eligibility Criteria:
Inclusion Criteria:

1. Preterm infants being treated with high flow nasal cannula therapy
2. A need for supplemental oxygen as demonstrated by an required FiO2 \> 0.25 at enrollment
3. Requiring a flow rate of greater than 2 L/min such that the assumed inspired oxygen fraction matched delivered oxygen fraction (definition of HFNC).

Exclusion Criteria:

1. Major congenital abnormalities
2. Hemodynamic instability, defined as being outside of a normotensive range based on each infant's individual characteristics
3. Seizures
4. Ongoing sepsis
5. Meningitis
6. Clinician's concern regarding stability of the infant
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma relapsed FIT or resistant to first line therapy.

The study aim is to evaluate the toxicity and activity of a therapeutic approach to high doses with support of peripheral blood stem cells (PBSC) in patients aged ≥ 65 and ≤75 years, chemosensitive relapsed or refractory to therapy first line in terms of event free survival (EFS) and treatment related mortality (TRM)

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of NHL
* relapse and refractory pts
* age ≥ 65 and ≤75
* ECOG performance status \<2
* FIT patients (Instrumental Activity of Daily Living (IADL)=8, Activity of Daily Living (ADL)=6, Cumulative Illness Rating Scale (CIRS) =0 SCORE=3-4, \<5 SCORE=2 )
* evaluable disease
* no RT since 3 week
* absolute neutrophil count \>= 1500/mm3 and platelets \>= 100.000/106L
* Creatinin \<= 1.5 mg/dL and clearance \>40 ml/min/24 h
* bilirubins \< =2 mg/dL
* forced expiratory volume \>50% - arterial pressure O2 \>70 mmHg
* no other neoplastic disease
* Life expectancy\> 3 months
* signed informed consent

Exclusion Criteria:

* HBV+ - HCV+ - HIV+
* NSC involvement - medullar infiltration \> 20%
* other chemotherapy or radiotherapy
* cardiac disease
* alteration of liver and kidney function
* infections
* demented patient
* no compliance and depressed pts
* Frail and Unfit pts
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation

18F-FDOPA PET-CT is currently the gold standard in the evaluation of Pheochromocytomas and Paragangliomas (PHEO - PGL) since these tumors can also decarboxylate amino acids such as dihydroxyphenylalanine (DOPA). This property is common to tumors of the APUD system (Amine Precursor Uptake and Decarboxylation). In recent years, PET (Positron Emission Tomography) imaging using peptide receptors has gained an increasing role in the management of NETs. The use of somatostatin agonists, radiolabeled with gallium-68 (68Ga) enables targeting of Somatostatin receptors (SSTRs) with a PET resolution. This has improved diagnosis of SSTRs-expressing tumors, including PGLs.

In the present study, the investigators have chosen DOTATATE (Nal3-octreotate) rather than other agonists (DOTATOC and DOTANOC), because of its higher affinity for SST2 which is the most overexpressed subtype in PHEO/PGL. However, performances of 18F-FDOPA PET-CT and 68Ga-DOTATATE PET-CT have never been compared in this clinical setting.


Eligibility Criteria:
Inclusion Criteria:

Age ≥ 18

* PHEO or PGL: initial staging or restaging
* Reference imaging within the last 2 months: multiphasic cervico-thoracoabdominal CT scan, 18F-FDOPA PET-CT and head and neck MRI (if head and neck localization

Exclusion Criteria:

Pregnant or breast-feeding woman
Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. Despite the advancement in anti-diabetic drug therapy, most patients fail to achieve optimal glycemic control. This highlights the need for more effective strategies to control type 2 diabetes mellitus.

Nitazoxanide (NTZ), a broad-spectrum anti-infective drug with activity against various protozoa, helminthes, bacteria, and viruses, was identified as peroxisome proliferative activated receptor gamma (PPARγ) agonist using one dimensional drug profile matching. Additionally, it improved insulin sensitivity in insulin-resistant type 2 diabetic rats. Therefore, this study is designed to evaluate the efficacy of nitazoxanide as adjunctive therapy in patients with type 2 diabetes mellitus.


Eligibility Criteria:
Inclusion Criteria:

* Glycated hemoglobin (HbA1c) between 7% and 9%.
* Body mass index ≥ 25 kg/m2

Exclusion Criteria:

* Pregnant or nursing women.
* Type 1 diabetes mellitus.
* Liver disease (alanine aminotransferase \> 3 upper normal limit).
* Kidney disease (estimated glomerular filtration rate \< 60 ml/min/1.73 m2).
* Inflammatory bowel diseases.
* History of allergy and/or adverse reactions to the drugs used in the study.
Ultrasound Guided Intra-uterine Device Insertion

Different studies have been made in an attempt to reduce the pain and the duration of the process of outpatient insertion of the intrauterine device. in this trial, the investigators aim to insert the IUD under ultrasonographic guidance, which can help to reduce the pain, decrease the process of insertion, in addition, it reduces the incidence of malposition of IUD as well as the risk of complications.


Eligibility Criteria:
Inclusion Criteria:

* Females desiring contraception with the use of IUD

Exclusion Criteria:

* Are pregnant or think they may be pregnant
* Septic pregnancy or abortion
* Have unexplained abnormal vaginal bleeding
* Have untreated cervical cancer
* Have malignant gestational trophoblastic disease
* Have uterine cancer
* Have uterine abnormalities
* Have or may have had a pelvic infection within the past three months
* Have or may have any sexually transmitted disease
* Have pelvic tuberculosis
* Are postpartum between 48 hours and 4 weeks
* Have benign gestational trophoblastic disease
* Have ovarian cancer
* Have AIDS (unless clinically well on anti-retroviral therapy)
Customized Polyamide Prosthesis. for Mid Shaft Clavicle Fracture

Herein we describe the management of a patient who presented with progressive brachial plexopathy following the initial nonoperative management of a mid shaft clavicular fracture by using 3 D customized polyamide prosthesis.

we made surgery to fix the new polyamide prosthesies in the clavicle.

Eligibility Criteria:
Inclusion Criteria:

* fracture midshaft clavicle

Exclusion Criteria:

* normal clavicle
Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome

The goal of this study is to examine in vivo thrombosis characteristics with ultrasound shear wave elastography (SWE) and determine the relationship with thrombus resolution and postthrombotic syndrome (PTS) in patients with acute proximal Deep Vein Thrombosis (DVT).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of acute, proximal (popliteal and above) DVT with or without Pulmonary Embolism within 72 hours
* ≥18 Years Old

Exclusion Criteria

* prior episode of DVT
* contraindication to standard therapeutic anticoagulation
PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery.

This is a single center, non-blinded randomized control trial taking place at the Queen Elizabeth II hospital (QEII) in Nova Scotia. Patients are eligible if aged 75 and older scheduled for elective cancer surgery (proven cancer or highly suspicious cancer) and screened to have mild or greater frailty (with cognitive impairments) or moderate to greater frailty (with medical/physical conditions). Eligible participants will then be randomized to preoperative standard of care or geriatric assessment through the PATH clinic. Primary outcome will assess time spend at home at 6 months after the surgery.

At Nova Scotia Health Authority (NSHA), geriatric medicine colleagues developed a preoperative palliative and therapeutic harmonization (PATH) clinic with the following objectives:

1. Assess medical conditions, health trajectory, and baseline frailty.
2. Conduct an in-depth discussion with the patient (or their substitute decision maker) to review medical conditions and how frailty stage impacts decision-making about surgery.
3. Co-develop a care plan, including ways to optimize health.

The investigators have elaborated a single center randomized cohort trial for patients aged 75 and older, screened as severely frail or cognitively impaired scheduled for curative or palliative-intent surgery for bronchopulmonary, oropharyngeal, orthopaedic, gynaecological, breast, genitourinary or gastrointestinal cancers (proven or clinically highly suspicious cancer).

Patients enrolled in the trial will be randomized to standard of care preoperative assessment versus PATH geriatric care arm.

Eligibility Criteria:
Inclusion Criteria:

1. Patients must have a clinically highly suspicious or pathologically confirmed diagnosis of bronchopulmonary, oropharyngeal (including head and neck surgery), orthopaedic, gynaecological, breast, genitourinary or gastrointestinal cancer surgery.
2. Patients must be scheduled and consented for curative or palliative intent surgery.
3. Patients must be aged 75 or older.
4. Patients must be screened by the CFS to have:

4a. Mild or greater frailty (CFS equal or greater than 5) due to cognitive impairment.

4b. Moderate or greater frailty (CFS equal or greater than 6) due to medical/physical conditions.

5. Informed consent for participation must be received.

Exclusion Criteria:

1. Patients cannot be a resident in a long-term care facility prior to the cancer diagnosis.
2. Urgent/ emergent cases are excluded.
Evaluation of Breathing Effort in Spontaneously Breathing Subjects

The aim of the research project is to evaluate the breathing effort using the Work of Breathing (WoB) and Pressure-Time Product (PTP) parameters, depending on the increasing flow resistance. The research project is concerned with assessing the increased (imposed) breathing effort using the Work of Breathing (iWoB) and the Pressure-Time Product (iPTP).

The main hypothesis tested is the differential effect of flow resistance on iWoB and iPTP parameters in spontaneous breathing of healthy probands.

Due to the different calculation of iWoB and iWoB, these parameters may be affected at higher flow resistance values. The proposed experiment will be used to compare iWoB and iPTP obtained during spontaneous breathing to healthy subjects.

Eligibility Criteria:
Inclusion Criteria:

* Healthy males and females \> 18 and \< 40 years old
* Signed informed consent has been obtained

Exclusion Criteria:

* Respiratory disease
* Pregnancy
* Cardiovascular disease
* Diabetes mellitus
Panitumumab IRDye800 Optical Imaging Study

Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

This is a Phase I trial that is designed to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 used in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent. Safety data from this trial will be studied to assist in the selection of dose levels of panitumumab-IRDye800 for future research. It is hoped that this study will also help in finding better methods for identifying cancer intraoperatively for a more complete surgical resection.

Eligibility Criteria:
Inclusion Criteria

* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
* Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
* Planned standard of care surgery with curative intent for squamous cell carcinoma
* Age ≥ 19 years
* Have life expectancy of more than 12 weeks
* Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
* Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count \> 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range

Exclusion Criteria

* Received an investigational drug within 30 days prior to first dose of panitumumab IRDye800
* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
* History of infusion reactions monoclonal antibody therapies
* Pregnant or breastfeeding
* Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
* Magnesium or potassium lower than the normal institutional values
* Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
* Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
* TSH \> 13 micro International Units/mL
Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome

A study to evaluate the role of forced oscillation in precocious diagnosis of bronchiolitis obliterans syndrome in patients with pulmonary transplant (time difference in detecting distal airways functional impairment by forced oscillation and the standard technique using spirometry).


Eligibility Criteria:
Inclusion Criteria:

* Patients of more than 18 year-old.
* Patients with cardiopulmonary transplant or bilateral lung transplant.
* Clinically stable patients

Exclusion Criteria:

* Patients already diagnosed with bronchiolitis obliterans.
* Respiratory infection.
* Acute graft rejection.
* Mechanical complications (bronchial dehiscence, pneumothorax, pleural effusion).
* Iatrogenic pneumopathy.
* Inability to perform Respiratory function test.
A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

This study is a Phase 2 randomized, double-blind, double-dummy, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT 122 in subjects with active rheumatoid arthritis (RA) who are inadequately responding to methotrexate (MTX) treatment.


Eligibility Criteria:
Inclusion Criteria:

1. Adult male or female, 18 years of age or older.
2. Diagnosis of RA based on the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria (as defined in the definition of terms).
3. Rheumatoid Arthritis (RA) diagnosis at least 3 months from the date of first Screening.
4. Have active RA defined by minimum disease activity criteria:

   * ≥ 6 Swollen joints (based on 66 joint counts) at screening and baseline visits.
   * ≥ 6 Tender joints (based on 68 joint counts) at screening and baseline visits.
   * hsCRP\> ULN OR positive for both Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody levels at screening.
5. Inadequate response to Methotrexate (MTX) treatment defined as oral or parenteral treatment ≥ 3 months with an unchanged mode of application and stable prescribed MTX dose for at least 4 weeks prior to baseline of ≥ 10mg/week and \< the upper limit of the applicable approved local label. Subject can also be on stable doses of sulfasalazine and/or hydroxychloroquine, so long as they are also on methotrexate.

Exclusion Criteria:

1. Subject has previous exposure to Humira, other Tumor necrosis factor (TNF) inhibitors or other biological DMARDs.
2. Current treatment with traditional oral Disease modifying antirheumatic drugs (DMARDs) (except for concomitant treatment with sulfasalazine and/or hydroxychloroquine in addition to MTX). Oral DMARDs must be washed out 5 times the mean terminal elimination half-life of a drug apart from MTX prior to Day 1.

   • Subject could have been exposed to prior Janus kinase (JAK) inhibitors so long as they have been off therapy for 5 half-lives.
3. Stable prescribed dose of oral prednisone or prednisone equivalent \> 10 mg/day within the 30 days of first dose of study drug.
4. Intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks of first dose of study drug. Inhaled corticosteroids for stable medical conditions are allowed.
5. Laboratory values of the following at the Screening Visit:

   * Confirmed hemoglobin \< 9 g/dL for males and \< 8.5 g/dL for females,
   * Absolute neutrophil count (ANC) \< 1500 mm\^3,
   * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 × the upper limit of normal (ULN) or bilirubin ≥ 3 mg/dL,
   * Serum creatinine \> 1.5 × the ULN,
   * Platelets \< 100,000 cells/\[mm3\] (10\^9/L),
   * Clinically significant abnormal screening laboratory results as evaluated by the Investigator.
Effects of Mulligan Mobilization With Movement as Compared to Kaltenborn Joint Mobilization in the Management of Knee Osteoarthritis

This study is a randomised controlled trial and the purpose of this study is to determine the Effects of Mulligan mobilization with movement as compared to Kaltenborn joint mobilization in the management of knee osteoarthritis." To determine the effects of Mulligan MWM as compared to Kaltenborn joint mobilization in terms of pain, function, range of motion and gait in persons with knee osteoarthritis.


Eligibility Criteria:
Inclusion Criteria:

* Individuals aged 40-70 years (Osama et al, 2022)
* Having KOA history of no less than 3 months
* Knee pain less than 8/10 on numeric pain rating scale (NPRS).
* Radiological evidence of grade III or less on Kellgren classification
* Patients referred from rehab department

Exclusion Criteria:

* Those with signs of serious pathology, such as malignancy, inflammatory disorder or infection.
* History of trauma or fractures in lower extremity.
* Signs of lumbar radiculopathy or myelopathy.
* History of knee surgery or replacement.
* Receiving intra-articular steroid therapy in the preceding two months.
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

The following study will hypothesizes that insulin resistance causes changes in drug metabolism, elimination, and effect. We will differentiate the insulin resistant phenotype amongst obese individuals on the basis of both laboratory (fasting insulin, triglycerides, fasting glucose) analysis, and quantitative and qualitative adiponectin expression. We will determine the effect of insulin resistance on the pharmacokinetics and pharmacodynamics of anesthetic induction agents and opioids, using propofol and fentanyl as examples.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria include patients of adult age
* American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia
* Body mass index greater than 35

Exclusion Criteria:

* Patients with evidence of hepatic, renal, or cardiovascular dysfunction
* History of difficult tracheal intubation, or adverse reaction to anesthesia shall be excluded from the study
* Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping aids, will also be excluded